it is difficult to explain how successful resuscitation is possible after 40 minutes' submersion.2 The reduced oxygen requirement in profound hypothermia has been suggested by some authors as the mechanism by which tissue viability is maintained in these circumstances,2 but this alone is an incomplete explanation, as for the submerged body to cool to a degree at which oxygen requirements are sufficiently reduced, heat transfer by mass flow-that is, circulation -must be present (a dead body cools relatively slowly). The degree of cooling encountered in our cases can be explained only by the fact that circulation was maintained for some or all of the period of submersion. The persistence of cardiac activity during such a prolonged period of apnoea supports the hypothesis that some protective mechanism may be present. We do not know whether ventricular fibrillation was present before resuscitative efforts were started and must concede that these efforts alone may have initiated the arrhythmia.
Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma Secretion of chenmical mediators from mast cells and contraction of bronchial smooth muscle are two major components in the pathogenesis of asthma. Both processes depend on the transmembrane passage of calcium ions, and drugs that inhibit this might therefore be expected to be of value in asthma. Cinnarizine, an antagonist to calcium transport, has been shown to exert a beneficial effect in patients with chronic asthma,' and verapamil, another calcium antagonist, prevents potassium-and serotonin-induced contraction of canine trachealis muscle.2 Nifedipine is a potent inhibitor of transmembrane calcium ion flux, and results of a recent study suggest that .~~~~~~~~~~~~~~~ĩ t prevents exercise-induced asthma. 3 We therefore investigated the effect of nifedipine on resting bronchomotor tone and on histamine reactivity in patients with asthma.
Patients, methods, and results
We studied 10 patients, aged 25-60 years, with chronic stable asthma. The protocol was approved by the hospital research ethics committee, and all subjects gave informed consent.
Each subject received either nifedipine 20 mg or placebo in a randomised double-blind fashion on separate days and was instructed to bite the capsules and keep the fluid in the mouth as long as possible. Both active and placebo capsules had the same appearance and contained liquid with an identical peppermint taste.
Using a dry spirometer, we measured forced expiratory volume in one second (FEV,), vital capacity (VC), and maximal mid-expiratory flow (MMEF) before and at 15, 30, 45, and 60 minutes after the capsules were taken. Blood pressure and heart rate were also recorded. After the measurements at 60 minutes histamine reactivity was assessed by giving the subjects serial dilutions of histamine acid phosphate solution to inhale via a Wright nebuliser. The concentration of histamine producing a 20 ,0 fall in FEV, (PC20) was calculated. Each subject received 200 jig inhaled salbutamol at the end of the study.
The studies were performed in an air-conditioned laboratory under constant environmental conditions. Both tests were performed at the same time of day in each subject, and the subjects had not taken any medication for at least eight hours beforehand.
No subject complained of any side effects, and there were no significant changes in blood pressure or heart rate. The lung function results are summarised in the spirometry between the days when nifedipine and placebo were taken. Although the increases in mean FEV1 and MMEF were both greater with nifedipine than placebo, an analysis of variance failed to show any significant difference between the two. PC2, was significantly greater (p < 005, paired t test) after nifedipine (0.42 10-14 mg histamine/ml) than placebo (0-15± 0 03 mg histamine/ml). All subjects showed a good bronchodilator response to inhaled salbutamol at the end of the study.
Comment
Although we were unable to show any significant bronchodilator activity for nifedipine, we showed that this drug provides a significant protective effect against histamine-induced bronchoconstriction. This suggests that it may have an effect on the contractility of bronchial smooth muscle, but the effect is too small to make oral nifedipine therapeutically useful in asthma. Our results clearly show, however, that nifedipine may safely be given to patients with asthma. Its clinical effectiveness in the treatment of angina is well documented, and there is some evidence that it produces an improvement in FEV1 when given to patients with angina and labile airways obstruction.4 Beta-adrenoreceptor antagonists have been the mainstay of antianginal treatment in recent years, but the use of such drugs in patients with asthma may be extremely hazardous.5 Patients with angina and coexistent asthma should be treated with nifedipine for their angina in preference to beta-blockers.
